Search This Blog

Monday, October 31, 2022

Lilly's Growth Tied to Nascent Diabetes Drug Sales

 Wall Street analysts will be focusing on sales of Eli Lilly and Co's newly approved diabetes drug Mounjaro when the company reports results on Tuesday, as sales of its older drugs come under pressure from increased competition and low pricing.

At least five analysts have raised their price target on the stock in the run-up to earnings on hopes that Mounjaro, which is approved to improve blood sugar levels in diabetics, will get U.S. approval for treating obesity next year.

"We remain bullish on Mounjaro's sales potential because we anticipate additional U.S. payer coverage this winter," SVB Securities analyst David David Risinger said in a research note on Monday.

The company's sales could quickly jump once Lilly gets more insurers to cover its costs, according to Risinger.

Obesity is the largest chronic health problem in the United States and also leads to many other illnesses such as liver disease and heart issues. Novo Nordisk's Wegovy is a rival treatment option for obesity.

Analysts expect Mounjaro sales of $81 million in the third quarter, months into its U.S. launch, according to Refinitiv data.

While that accounts for just a fraction of Lilly's total sales, revenue from the drug is expected to cross the $1 billion mark next year as it gains approval for obesity and other conditions.

Lilly's sales are expected to increase to $30.23 billion in 2023, versus reported sales of $24.54 billion in 2021, with Mounjaro expected to bring in $1.34 billion in sales and become the company's third-biggest selling drug, according to Refinitiv data.

https://money.usnews.com/investing/news/articles/2022-10-31/eli-lillys-growth-tied-to-nascent-diabetes-drug-sales

Biden offers prominent NY rabbi 'open door to my admin' to back Maloney

 

  • Tasked with leading Democrats in their fight to keep the House, DCCC chair Maloney must now focus on his own NY race against Republican Mike Lawler
  • 'You will have an open door to my administration,' Biden reportedly promised Rabbi David Twersky in a 15-minute phone call
  • Political strategist Hank Sheinkopf said Twersky is revered by Hasidic Jews in New Square and they will heed his advice and vote for Maloney if he tells them to
  • The phone call suggests Democrats are worried about Maloney's race which has recently been rated a 'toss-up' 

President Biden called a prominent New York rabbi and offered him unfettered access to the White House in exchange for throwing his support behind Rep. Sean Patrick Maloney, chair of the Democrat's campaign arm who is locked in a tight race. 

Tasked with leading Democrats in their fight to keep the House, Democratic Congressional Campaign Committee (DCCC) chair and New York Rep. Maloney must now focus on his own race against Republican assemblyman Mike Lawler on Nov. 8. It has turned into a 'toss-up' race, despite Biden carrying the district by 10 points. 

'You will have an open door to my administration,' Biden promised Rabbi David Twersky in a 15-minute phone call, according to Rockland Daily. Jewish Forward reporter Jacob Kornbluh confirmed the call. 

Twersky is the chief rabbi for the Hasidic sect in New Square, N.Y. in the 17th Congressional District. 

The phone call came before First Lady Jill Biden heads to Mount Kisko, N.Y. on Sunday for a political finance event with Maloney.  

New York-based political strategist Hank Sheinkopf said Twersky is revered by Hasidic Jews in New Square and they will heed his advice and vote for Maloney if he tells them to do so. 

Sheinkopf also said the call signals trouble for Maloney. 

'You don't have the President of the United States call someone for support unless you're in trouble in a political campaign,' he told the New York Post. 'If you're up by 10 points, you don't ask the president for help.' 

'For all his fake bravado, Sean Patrick Maloney sure is behaving like a very scared man,' National Republican Congressional Campaign (NRCC) spokesperson Samantha Bullock told DailyMail.com. 'Maloney's fellow vulnerable Democrats are probably less than thrilled their DCCC chair is using whatever political capital he has left to try and save himself.' 

Maloney's campaign could not be reached for comment on the matter.  

Earlier this month Biden stumped for Democrats in Poughkeepsie, where he was joined by Maloney and New York Gov. Kathy Hochul. Hochul is facing an increasingly competitive challenge from GOP Rep. Lee Zeldin. 

On Sunday Hochul met with ultra-religious Jewish leaders in Rockland County as she fights for the orthodox Jewish vote against Zeldin, who is Jewish. 

Jewish groups hailed Maloney's win over progressive challenger Alessandra Biaggi in August's primary, as Biaggi had expressed support for the boycott, divest and sanctions (BDS) movement against Israel.

Meanwhile, Republicans are pouring in funds to defeat the Democrat Party leader. The Congressional Leadership Fund, a super PAC aligned with House Republican Leadership, has dumped $6 million into the race, including $4 million announced just last week. 

They're shifting the focus back to crime, with ads highlighting Maloney's 2018 comments calling ending cash bail reform a 'top priority.' 

The race for the newly drawn district comes after a messy redistricting process that split the DCCC chair's district in two. Instead of running in the current version of his district, he ran in the more Democratic-leaning new district where his house is located, pushing out progressive Rep. Mondaire Jones. Jones subsequently ran in a New York City district's primary and lost. Maloney's handling of the process drew sharp intra-party criticism. 

Complaints also arose across the nation about Maloney over the DCCC's choice to elevate far-right candidates in Republican primaries who they believed they would have an easier time beating in general elections. 

New GOP funding for Lawler led the DCCC to put up a $600,000 buy in TV ads, with some other vulnerable Democrats voicing frustration that the party has had to dip into its coffers to save its chairs rather than focusing on helping others who are under water. 

Maloney also prompted questions when he paid his and his husband's personal trainer over $7,000 from campaign and taxpayer funds, as DailyMail.com first reported. A Maloney spokesperson said the trainer, Erick Ramos, was paid as a part-time driver for the congressman. 

Maloney's staffing choices have raised eyebrows as to whether he used campaign funds for personal use before. In July the New York Post reported on Harold Leath, Maloney's former 'body man' or as Maloney's office calls it, 'executive assistant.'  

'I was pretty much with the congressman everywhere he went within the district — if he went to a meeting, if he went out running. I would drive him everywhere he needed to go,' he told The Post.

'When I first started, my main responsibility was to make sure the congressman and his family never needed anything,' Leath recalled. 'I was to be there.'

'Everything I got paid for was either for his campaign, in the beginning, or doing something for him.'

https://www.dailymail.co.uk/news/article-11361203/Biden-calls-New-York-rabbi-offer-open-door-throws-support-Sean-Patrick-Maloney.html

Leaked Docs Reveal Shocking Extent Of DHS 'Disinfo' Collusion With Twitter, Facebook

 In August, Meta CEO Mark Zuckerberg admitted on the Joe Rogan podcast that the FBI approached the company warning of "Russian propaganda" shortly before the Hunter Biden laptop story broke at the NY Post.

"Basically, the background here is the FBI, I think, basically came to us- some folks on our team and was like, 'Hey, just so you know, like, you should be on high alert…  We thought that there was a lot of Russian propaganda in the 2016 election. We have it on notice that, basically, there's about to be some kind of dump of that's similar to that. So just be vigilant," Zuckerberg told Rogan.


Now, leaked documents provided to The Intercept reveal that government collusion with big tech goes much deeper.

The effort began in 2018, after former President Donald Trump signed the Cybersecurity and Infrastructure Security Agency Act in the wake of several high-profile hacking incidents, forming a new wing of DHS devoted to protecting critical national infrastructure.

The Department of Homeland Security is quietly broadening its efforts to curb speech it considers dangerous, an investigation by The Intercept has found. Years of internal DHS memos, emails, and documents — obtained via leaks and an ongoing lawsuit, as well as public documents — illustrate an expansive effort by the agency to influence tech platforms.

The work, much of which remains unknown to the American public, came into clearer view earlier this year when DHS announced a new “Disinformation Governance Board”: a panel designed to police misinformation (false information spread unintentionally), disinformation (false information spread intentionally), and malinformation (factual information shared, typically out of context, with harmful intent) that allegedly threatens U.S. interests. While the board was widely ridiculed, immediately scaled back, and then shut down within a few months, other initiatives are underway as DHS pivots to monitoring social media now that its original mandate — the war on terror — has been wound down.

Behind closed doors, and through pressure on private platforms, the U.S. government has used its power to try to shape online discourse. According to meeting minutes and other records appended to a lawsuit filed by Missouri Attorney General Eric Schmitt, a Republican who is also running for Senate, discussions have ranged from the scale and scope of government intervention in online discourse to the mechanics of streamlining takedown requests for false or intentionally misleading information. -The Intercept

"Platforms have got to get comfortable with gov’t. It’s really interesting how hesitant they remain," said Microsoft exec and former DHS official Matt Masterson in a February text to Jen Easterly, a DHS director.

Then, in a March 2022 meeting, FBI official Laura Dehmlow warned that the 'threat of subversive information on social media' could undermine support for the US government - stressing "we need a media infrastructure that is held accountable."

Twitter has denied the report, telling The Intercept: "We do not coordinate with other entities when making content moderation decisions, and we independently evaluate content in line with the Twitter Rules."

Except...

More via The Intercept:

This apparatus had a dry run during the 2020 election, when CISA began working with other members of the U.S. intelligence community. Office of Intelligence and Analysis personnel attended “weekly teleconferences to coordinate Intelligence Community activities to counter election-related disinformation.” According to the IG report, meetings have continued to take place every two weeks since the elections.

Emails between DHS officials, Twitter, and the Center for Internet Security outline the process for such takedown requests during the period leading up to November 2020. Meeting notes show that the tech platforms would be called upon to “process reports and provide timely responses, to include the removal of reported misinformation from the platform where possible.” In practice, this often meant state election officials sent examples of potential forms of disinformation to CISA, which would then forward them on to social media companies for a response.

Under President Joe Biden, the shifting focus on disinformation has continued. In January 2021, CISA replaced the Countering Foreign Influence Task force with the “Misinformation, Disinformation and Malinformation” team, which was created “to promote more flexibility to focus on general MDM.” By now, the scope of the effort had expanded beyond disinformation produced by foreign governments to include domestic versions. The MDM team, according to one CISA official quoted in the IG report, “counters all types of disinformation, to be responsive to current events.”

What's more, the DHS plans to accelerate their efforts.

According to a draft copy of DHS’s Quadrennial Homeland Security Review, DHS’s capstone report outlining the department’s strategy and priorities in the coming years, the department plans to target “inaccurate information” on a wide range of topics, including “the origins of the COVID-19 pandemic and the efficacy of COVID-19 vaccines, racial justice, U.S. withdrawal from Afghanistan, and the nature of U.S. support to Ukraine.”

Why? Racism, apparently.

"The challenge is particularly acute in marginalized communities, which are often the targets of false or misleading information, such as false information on voting procedures targeting people of color," reads the report.

Read more here...

Stryker Corp. stock falls after company lowers outlook for 2022

 Shares of Stryker Corp. fell more than 4% in the extended session Monday after the maker of surgical equipment and other medical devices reported third-quarter results above analyst expectations but lowered its profit outlook for the year, thanks to inflation and a stronger dollar. Striker earned $816 million, or $2.14 a share, in the quarter, compared with $495 million, or $1.14 a share, in the year-earlier period. Adjusted for one-time items, Stryker earned $2.12 a share. Sales rose to $4.48 billion, from $4.16 billion. Analysts polled by FactSet expected GAAP earnings of $1.77 a share on sales of $4.46 billion. "Worsening foreign currency and ongoing inflation, including premiums on spot buys for key components, pressured our adjusted earnings and will impact our full year results. We are taking additional actions to address these persistent issues," Chief Executive Kevin Lobo said in a statement. Stryker said it expects 2022 net sales to be "adversely impacted" by about 4%, and adjusted EPS down by about 35 cents to 40 cents in the year. It called for adjusted EPS between $9.15 a share and $9.25 a share for the year considering the "continued inflationary pressures" as well as a stronger dollar. In July, the company guided for adjusted EPS between $9.30 and $9.50 for the year. Shares of Stryker ended the regular trading day flat.

https://www.morningstar.com/news/marketwatch/20221031605/stryker-corp-stock-falls-after-company-lowers-outlook-for-2022

Dangerous ‘Barbie’ tanning drug’s popularity rises despite serious side effects

 An illegal tanning drug referred to as the “Barbie drug” has risen in popularity through TikTok, prompting a warning from Australia’s Therapeutic Goods Administration of its dangers.

Melanotan is being promoted across social media as a long-lasting fake tan alternative, but the TGA warned it has “proven, serious side effects that can be very damaging to your health”.

“Side-effects include darkened skin, increased moles and freckles, nausea, vomiting, loss of appetite, flushing of the face, involuntary stretching and yawning, and spontaneous erections,” the TGA said.

There are also concerns the drug may increase the risk of skin cancer in the form of melanoma, according to the New Zealand Dermatological Society.

After an initial warning in 2017, a growing number of videos and accounts on TikTok promoting the drug in nasal spray form as a safer alternative to tanning led to the TGA renewing its advice on Friday.

“The Therapeutic Goods Administration urges consumers to steer clear of using products containing ‘Melanotan’ without advice from a medical professional,” it said.

“Regardless of how the product enters the body, the associated risks remain and are not new.

A popular tanning drug making the rounds on social media is dangerous, experts warn.
A popular tanning drug making the rounds on social media is dangerous, experts warn.
TikTok / georgiafox11

“These products are not included on the Australian Register of Therapeutic Goods (ARTG) and have not been assessed for quality, safety or efficacy by the TGA. This makes it illegal to advertise or supply them.”

Despite this, websites advertising the drug’s sale are readily accessible online.

“What if there was a way for you to get that perfect tan you’ve always dreamed of without any of the negative side-effect (sic),” one said.

Melantonin could potentially cause skin cancer.
Melantonin could potentially cause skin cancer.
TikTok / georgiafox11

Another business, operating as an Australian outlet, avoids any mention of its operation’s illegality as it explains to customers the only payment option is directly into a bank account.

“We are no longer able to process credit card payments due to being in the pharmaceutical industry and transactions being labelled as high risk and to get approved for a merchant account or payment gateway to process payments is near impossible to all businesses within this industry,” Melanotan Australia’s website reads.

According to the TGA, as well as the importing of Melanotan being illegal, it also presents a risk of customers losing their money.

“Side-effects include darkened skin, increased moles and freckles, nausea, vomiting, loss of appetite, flushing of the face, involuntary stretching and yawning, and spontaneous erections,” experts warned.
“Side-effects include darkened skin, increased moles and freckles, nausea, vomiting, loss of appetite, flushing of the face, involuntary stretching and yawning, and spontaneous erections,” experts warned.
TikTok / georgiafox11

“Despite some websites appearing to be Australian, these products are quite often coming from an overseas source,” it said.

detained at the border, you will not receive your goods, you will lose your money and there may be penalties if you are involved in promotion or sale of these products.”

The TGA also reminded Australians they can report the promotion or sale of banned substances such as Melanotan.

https://nypost.com/2022/10/31/dangerous-barbie-tanning-drugs-popularity-rises-despite-serious-side-effects/

NGM Biopharmaceuticals Insider Buys

 Insider Transactions

Currency in USD
Insider Purchases Last 6 MonthsSharesTrans
Purchases4,159,47623
SalesN/A0
Net Shares Purchased (Sold)4,159,47623
Total Insider Shares Held17.11MN/A
% Net Shares Purchased (Sold)32.10%N/A

RBC Cuts Price Target on Amedisys to $139 From $165 After 'Difficult' Q3

 Maintains Outperform Rating

https://www.marketscreener.com/quote/stock/AMEDISYS-INC-8342/news/RBC-Cuts-Price-Target-on-Amedisys-to-139-From-165-After-Difficult-Q3-Maintains-Outperform-Ratin-42135800/

Inactivated SARS-CoV-2 and spike mRNA vaccines trigger different T-cell responses

 The total magnitude of the T-cell responses induced by mRNA and inactivated SARS-CoV-2 vaccines are comparable; however, the similarity ends here, according to a new study led by Duke-NUS Medical School scientists.

They found that the inactivated vaccines, which expose the  to the entire non-viable virus, elicit a broad  against different proteins on the virus. Publishing in Cell Reports Medicine, the findings add to the growing literature that will help scientists improve vaccine strategies for an ever-changing virus.

"Inactivated SARS-CoV-2 vaccines were used extensively in Asia, but are often considered inferior due to their induction of a lower antibody response compared to other types of vaccines," said Dr. Anthony Tanoto Tan, Senior Research Fellow with the Duke-NUS' Emerging Infectious Diseases (EID) Program and a senior co-author of the study. "This means that they might not have been as good at preventing infection, but several studies have shown that they are highly capable of thwarting the development of severe COVID-19."

The research team compared the T-cell immune response in  from people who received inactivated SARS-CoV-2 and spike mRNA vaccines. While mRNA vaccines can only induce T cells targeting SARS-CoV-2's spike protein, which contains numerous mutations in the , the inactivated vaccines stimulated a broad T-cell response not only against the virus's spike protein, but also the membrane and nucleoprotein that has much fewer mutations in omicron.

"This combination of membrane, nucleoprotein and spike-specific T-cell response is quantitatively comparable to the sole spike T-cell response induced by the mRNA . It also effectively tolerates the mutations characterizing the omicron lineage," said Ms. Joey Lim Ming Er, first author of the study and a second-year student Ph.D. with the Integrated Biology and Medicine Ph.D. track at Duke-NUS.

However, unlike the mRNA vaccines, the inactivated virus vaccines did not appear to trigger cytotoxic CD8 T cells known for their ability to kill virus-infected cells. They mainly stimulated a type of T cells called CD4 T helper cells. When these T cells recognize a viral antigen, they release chemicals, called cytokines that helps the activation other types of immune cells, hence their name.

Senior author of the study Professor Antonio Bertoletti from Duke-NUS' EID Program said, "The omicron variant can effectively evade antibody neutralization, moving the evaluation of vaccination efficacy away from preventing infection and towards ameliorating disease. T cells are likely to play a more important role in this compared to antibodies, due to their ability to target virus-infected cells.

"Since inactivated SARS-CoV-2 vaccines can generate T cell responses towards other , this more heterogenous response could be beneficial, in comparison to the current Spike targeting strategy of other vaccines. However, larger studies are needed to clarify the impact of these T cells responses in SARS-CoV-2 pathogenesis to better design vaccines for controlling severe COVID-19 after infection by omicron or future variants."

To dig deeper into the implications of the different T-cell responses, the scientists called for further research with larger numbers of participants, to compare the ability of the multi-protein CD4 T cell response induced by inactivated virus vaccines with that of the single spike protein coordinated CD4 and CD8 T cell response induced by mRNA vaccines to ameliorate COVID-19 disease severity.


Explore further

COVID-19 vaccine given at two- or four- week interval results in similar immunity

More information: Joey Ming Er Lim et al, A comparative characterization of SARS-CoV-2-specific T cells induced by mRNA or inactive virus COVID-19 vaccines, Cell Reports Medicine (2022). DOI: 10.1016/j.xcrm.2022.100793
https://medicalxpress.com/news/2022-10-inactivated-sars-cov-spike-mrna-vaccines.html

Anti-inflammatory molecules that decline in the aging brain

 Aging involves complicated plot twists and a large cast of characters: inflammation, stress, metabolism changes, and many others. Now, a team of Salk Institute and UC San Diego scientists reveal another factor implicated in the aging process—a class of lipids called SGDGs (3-sulfogalactosyl diacylglycerols) that decline in the brain with age and may have anti-inflammatory effects.

The research, published in Nature Chemical Biology on October 20, 2022, helps unravel the molecular basis of brain aging, reveals new mechanisms underlying age-related neurological diseases, and offers future opportunities for therapeutic intervention.

"These SGDGs clearly play an important role in aging, and this finding opens up the possibility that there are other critical aging pathways we've been missing," says co-corresponding author Alan Saghatelian, professor in Salk's Clayton Foundation Laboratories for Peptide Biology and holder of the Dr. Frederik Paulsen Chair. "This is a pretty clear case of something that should be dug into more in the future."

SGDGs are a class of lipids, also called fats. Lipids contribute to the structure, development, and function of healthy brains, while badly regulated lipids are linked to aging and diseased brains. However, lipids, unlike genes and proteins, are not well understood and have often been overlooked in aging research. Saghatelian specializes in discovering new lipids and determining their structures.

His lab, in collaboration with Professor Dionicio Siegel at UC San Diego, made three discoveries involving SGDGs: In the brain,  levels are very different in older mice than in younger mice; all SGDG family members and related lipids change significantly with age; and SGDGs may be regulated by processes that are known to regulate aging.

To reach these findings, the team took an unusual, exploratory approach that combined the large-scale study of lipids (lipidomics) with structural chemistry and advanced data analytics. They first obtained lipid profiles of mouse brains at five ages, ranging from one to 18 months, using liquid chromatography-mass spectrometry.

Technological advances in this instrumentation vastly expanded the number of data points available to the scientists, and advanced data analysis allowed them to determine age-related patterns in the enormous lipid profiles. The team then constructed SGDG molecules and tested them for biological activity.

"SGDGs were first identified in the 1970s, but there were few follow-up studies. These lipids were essentially forgotten and missing from the lipid databases. Nobody knew SGDGs would be changing or regulated in aging, let alone that they have bioactivity and, possibly, be therapeutically targetable," says first author Dan Tan, a postdoctoral fellow in Saghatelian's lab at Salk.

The analysis showed that SGDGs possess anti-inflammatory properties, which could have implications for neurodegenerative disorders and other neurological conditions that involve increased inflammation in the brain.

The team also discovered that SGDGs exist in human and primate brains, suggesting that SGDGs may play an important role in animals other than mice. Further research will be required to show if SGDGs contribute to human neuroinflammation.

In the future, the team will examine how SGDGs are regulated with aging and what proteins are responsible for making them and breaking them down, which may open the door to discovering novel genetic activity associated with aging.

"With the understanding of the structure of SGDGs and our ability to create them in the laboratory, the study of these important lipids is now wide open and ripe for discovery," says Siegel, co-corresponding author of the study.


Explore further

Association between blood plasma lipids and risk of Alzheimer's disease

More information: Dan Tan et al, A class of anti-inflammatory lipids decrease with aging in the central nervous system, Nature Chemical Biology (2022). DOI: 10.1038/s41589-022-01165-6
https://medicalxpress.com/news/2022-10-scientists-anti-inflammatory-molecules-decline-aging.html

Best blood thinner for minimizing bleeding risk

 A large-scale comparison of direct oral anticoagulants (blood thinners), commonly prescribed for irregular heartbeats, has identified the drug associated with the lowest risk of bleeding, in a new study led by UCL researchers.

In the paper published in Annals of Internal Medicine, the researchers report that one of the two most common direct oral anticoagulants (DOACs), apixaban, offers the lowest risk of gastrointestinal bleeding, with similar performance on  and other side effects.

DOACs are used to prevent strokes for people with —slow or —a condition affecting over 33 million people worldwide. They have recently become more common than warfarin, the previous standard treatment, as they do not require as much follow-up monitoring (which was particularly valuable during the COVID-19 pandemic) and carry less risk of side effects.

For the new study, the researchers compared the efficacy and risk of side effects for the four most common DOACs. They reviewed data from more than 500,000 new DOAC users in the UK, France, Germany and the US, including 281,320 apixaban users, 61,008 dabigatran users,12,722 edoxaban users, and 172,176 rivaroxaban users.

They found that all four drugs were comparable on outcomes for , brain bleeds and all-cause mortality, while they did identify a difference in risk of gastrointestinal bleeding, which is one of the most common and concerning side effects of DOACs.

The study revealed that apixaban stood out as having lower risk of gastrointestinal bleeding, with 19-28% lower risks when compared directly to each of the other three DOACs.

The researchers found that their findings held true when looking at data only from those aged over 80, and those with , two groups that are often underrepresented in clinical trials.

Co-lead author Dr. Wallis Lau (UCL School of Pharmacy) said, "Direct oral anticoagulants have been prescribed with increasing frequency worldwide in recent years, but evidence comparing them directly has been limited. Our results indicate that  may be preferable to other  because of the lower rate of gastrointestinal bleeding and similar rates of stroke, a finding that we hope will be supported by randomized controlled trials.

"As with all medications, potential risks and benefits can differ between people, so considering the full spectrum of outcomes and side effects will still be necessary for each individual patient."


Explore further

Study of claims data compares apixaban vs rivaroxaban for patients with atrial fibrillation and valvular heart disease

More information: Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation, Annals of Internal Medicine (2022). DOI: 10.7326/M22-0511
https://medicalxpress.com/news/2022-10-blood-thinner-minimizing.html

Invitae: therapy informed by genetic testing reduces seizures in some patients with epilepsy

 Invitae (NYSE: NVTA), a leading medical genetics company, today announced the findings of a study that documents the actions clinicians take upon receiving a positive diagnostic genetic testing result for patients with epilepsy. The findings, in JAMA Neurology, demonstrate that a positive genetic diagnosis leads to clinical management changes in approximately half of patients and that changes implemented by clinicians based on genetic testing improve health outcomes in as many as three quarters of patients. When a change in management is made based on the results of a positive genetic test result, outcomes for patients with epilepsy generally improve, including reduction, and even complete elimination of seizures. 

This study addresses a longstanding gap in understanding clinician action once positive genetic results are found for patients with epilepsy. A definitive molecular diagnosis obtained from epilepsy genetic testing led to important changes in clinical management that ultimately improved outcomes for patients. These changes included initiating medication, adding a new medication, or stopping a medication, and were made for half of the patients in the study within three months of testing. For patients with treatment changes, 75% were reported to have positive health outcomes including 65% who had reduction in seizure frequency and in some cases elimination of seizures.  

https://www.marketscreener.com/quote/stock/INVITAE-CORPORATION-23400709/news/Invitae-study-shows-therapy-informed-by-genetic-testing-reduces-seizures-in-some-patients-with-epile-42157626/